Almudena Romero-Layos
Albacete, CM, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.
Journal: Cephalalgia : an international journal of headache
Published: June 19, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
Journal: Neurology
Published: May 27, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
Journal: Neurology
Published: January 28, 2026
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response.
Journal: The journal of headache and pain
Published: October 31, 2025
New therapeutic era for migraine attacks with recently approved monoclonal antibodies, ditans and gepants
Journal: Revista de neurologia
Published: January 15, 2024
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 27, 2023
Knowledge about oral preventive treatments in patients with migraine: A nationwide study.
Journal: Neurologia
Published: August 21, 2022
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients.
Journal: Cephalalgia : an international journal of headache
Published: February 15, 2022
Persistent headache after COVID-19: Pathophysioloy, clinic and treatment.
Journal: Neurology perspectives
Published: August 01, 2021
Erenumab for the treatment of chronic resistant migraine.
Journal: Medicina clinica
Published: February 13, 2021
Last Updated: 09/26/2026